Moderna, Inc.(MRNA) - Stock detail

Moderna, Inc.

US
MRNA
Moderna, Inc.(Listing date: 12/07/2018)

Moderna, Inc. was incorporated under Delaware law on July 22, 2016. The company is a leader in the field of messenger ribonucleic acid (mRNA) medicine. Through more than a decade of work at the intersection of science, technology, and health, the company has developed drugs with unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines. The company's mRNA platform has enabled the development of therapies and vaccines for infectious diseases, immuno-oncology, rare diseases, and autoimmune diseases. With a unique culture and a global team driven by Moderna's values and mindset, the company strives to transform the future of human health in a responsible manner and to deliver the greatest possible impact to people through mRNA medicines.

AI Rating

Rating methodology
Latest close (chg%)49.06+7.49%
Buy price
49.06
Target price38.00
Sell price50.00
P/E TTM-7.55
P/E-5.14
Confidence85%
Risk score85/100
AI Summary
Committee decision based on catastrophic fundamentals (-$1.34B Q1 loss, -145% gross margin), overvaluation (P/S 8.75), and asymmetric risk around June 18 FDA panel where positive outcome is likely priced in at current elevated levels. Technicals show overbought rally within larger downtrend.

Alpha Score

0-10
  • Trend（Score 4/10）

    Technical indicators show a mixed but cautiously improving picture following a significant recent price surge, with short-term momentum turning bullish but requiring further confirmation.

  • Valuation（Score 2/10）

    Valuation analysis indicates the stock appears overvalued based on traditional metrics, with a high Price-to-Sales ratio of 8.75 and negative P/E ratios. The current price of $49.06 is not supported by profitability metrics and is driven entirely by future pipeline potential expectations.

  • Financial strength（Score 6/10）
    Financial condition assessment shows mixed signals with strong liquidity metrics but concerns about sustainability given negative profitability. The company maintains moderate leverage and sufficient short-term liquidity, but sustained losses will gradually erode cash reserves.
  • Profitability（Score 2/10）
    Profitability analysis reveals severe challenges with significant net losses, negative gross margins, and negative return metrics. The company is experiencing profitability pressures as it transitions beyond COVID-19 revenue, with massive costs offsetting revenue growth.
  • Sentiment（Score 8/10）
    Moderna is experiencing significant operational momentum and positive market sentiment driven by pipeline expansion, strategic partnerships, and analyst upgrades, creating a strong near-term catalyst environment.
Latest price
$49.06+7.49%
Market cap19.47B
P/E TTM-7.55
P/E-5.14
Volume6.91M
Turnover325.91M